Table 1 Baseline Characteristics

Number of patients, n

105

105

ns

Gender (male/female),n

92/13

92/13

ns

Age (years), mean ± SD

65.4 ± 9.4

63.3 ± 5.5

ns

BMI (Kg/m2), mean ± SD

28.3 ± 3.4

28. ± 5 4

ns

Serum creatinine (mg/dl), mean ± SD

1.12 ± 0.3

1.04 ± 0.2

ns

CLINICAL HISTORY

   Angina, n (%)

54 (51%)

62 (59%)

ns

   Inconclusive stress test, n(%)

56 (53%)

62 (58%)

ns

   Valvular disease, n (%)

0 (0%)

2 (2%)

ns

   Arrhytmia, n (%)

0 (0%)

2 (2%)

ns

   DCM, n (%)

12 (8%)

10 (9.5%)

ns

CARDIOVASCULAR RISK FACTORS

   Diabetes mellitus, n (%)

105 (100%)

0 (0%)

0.01

   Insulin dependent, n (%)

12 (11.5%)

-

-

   Glycosylated haemoglobin (%)

7.1 ± 2.4%

-

-

   Hypertension, n (%)

74 (70%)

63 (60%)

ns

   Hypercholesterolemia, n (%)

59 (56%)

45 (43%)

ns

   Current smoking, n (%)

31 (30%)

29 (28%)

ns

   Family history of CAD, n (%)

21 (20%)

27 (26%)

ns

PRE-TEST LIKELIHOOD OF CAD

51%

52%

ns

β-BLOCKER

   Number of patients, n (%)

66 (63%)

63 (60%)

ns

   Dose (mg), mean ± SD

11.2 ± 5.3

11.4 ± 2.5

ns

HEART RATE (bpm), mean ± SD

61.2 ± 9.3

58 ± 4.6

ns

AGATSTON SCORE

   mean ± SD

479 ± 492

356 ± 367

0.01

   median (range)

346 (0-1740)

240 (0-1650)

0.01

CAD extension

   0-vessel, n (%)

10 (11%)

18 (13%)

ns

   1-vessel, n (%)

28 (27%)

20 (19%)

ns

   2-vessel, n (%)

33 (30%)

34 (34%)

ns

   3-vessel, n (%)

34 (32%)

33 (34%)

ns